首页> Clinical cancer research : an official journal of the American Association for Cancer Research> Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).

导出 OA

翻译打印收藏纠错

第一作者： Shannon L,Puhalla

第一单位： University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania. puhallasl@upmc.edu.

作者： Shannon L,Puhalla ^[1] ; Véronique,Diéras ^[2] ; Banu K,Arun ^[3] ; Bella,Kaufman ^[4] ; Hans,Wildiers ^[5] ; Hyo S,Han ^[6] ; Jean-Pierre,Ayoub ^[7] ; Vered,Stearns ^[8] ; Yuan,Yuan ^[9] ; Teresa,Helsten ^[10] ; Bridget,Riley-Gillis ^[11] ; Erin,Murphy ^[11] ; Madan G,Kundu ^[11] ; Meijing,Wu ^[11] ; David,Maag ^[11] ; Christine K,Ratajczak ^[11] ; Cyril Y,Ramathal ^[11] ; Michael,Friedlander ^[12]

作者单位： University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania. puhallasl@upmc.edu. ^[1] Institut Curie, Paris, France.;Centre Eugène Marquis, Rennes, France. ^[2] The University of Texas MD Anderson Cancer Center, Houston, Texas. ^[3] Sheba Medical Center, Tel Hashomer, Israel. ^[4] University Hospitals Leuven, Leuven, Belgium. ^[5] Moffitt Cancer Center, Tampa, Florida. ^[6] Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada. ^[7] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. ^[8] City of Hope Cancer Center, Duarte, California. ^[9] University of California San Diego Moores Cancer Center, La Jolla, California. ^[10] AbbVie Inc., North Chicago, Illinois. ^[11] Prince of Wales Clinical School UNSW and Prince of Wales Hospital, Sydney, New South Wales, Australia. ^[12]